Updated NETs Clinical Trials

1. SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

   Conditions: Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma Interventions: Drug: SNC115 injection Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Shanghai Chest Hospital Recruiting

2. NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

   Conditions: Metastatic Neuroendocrine Prostate Cancer Interventions: Drug: [68Ga]Ga-PSMA-11; Drug: [68Ga]GA-DOTA-TATE; Drug: [68Ga]Ga-NeoB; Drug: [177Lu]Lu-PSMA-617; Drug: [177Lu]Lu-DOTA-TATE; Drug: [177Lu]Lu-NeoB; Drug: L-Lysine HCl-L-Arginine HCl, 2.5 %,; Drug: Gonadotropin-releasing hormone (GnRH) analogues; Drug: GnRH antagonists; Drug: Antiemetics & antinauseants; Drug: Metoclopramide Sponsors: Novartis Pharmaceuticals Not yet recruiting

3. Using the EHR to Advance Genomic Medicine Across a Diverse Health System

   Conditions: Genetic Predisposition; Paraganglioma; Pheochromocytoma; ALS; Parkinson Disease; Polyneuropathies; Frontotemporal Dementia; Alzheimer Disease; Cardiomyopathy Non-ischemic; Thoracic Aortic Aneurysm Interventions: Behavioral: Behavioral nudge Sponsors: University of Pennsylvania Not yet recruiting

4. Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.

   Conditions: Neuroendocrine Carcinoma Interventions: Biological: ZG005; Drug: Etoposide; Drug: Cisplatin; Drug: Placebo Sponsors: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Not yet recruiting

5. Ex-vivo Ultrasound Guided Radiofrequency Ablation on Pancreatic Solid Lesions

   Conditions: Pancreatic Cancer; Endoscopic Ultrasound; Radiofrequency Ablation Interventions: Procedure: ex-vivo RFA under US control at 10 Watts (W) of power in 3 differents arms of lesions; Procedure: ex-vivo RFA under US control at 30 Watts (W) of power in 3 differents arms of lesions; Procedure: ex-vivo RFA under US control at 50 Watts (W) of power in 3 differents arms of lesions Sponsors: IRCCS San Raffaele Terminated

6. Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

   Conditions: Neuroendocrine Carcinoma; Non-small Cell Lung Cancer; Histology Transformation Sponsors: Fudan University Recruiting

7. Chemotherapy Followed by Response-Based Reduced Radiation Therapy for Patients With Central Nervous System Germinomas

   Conditions: Intracranial Germ Cell Tumor; Childhood Central Nervous System Germinoma Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy; Drug: Carboplatin; Drug: Etoposide; Radiation: Intensity-Modulated Radiation Therapy Sponsors: Children's Oncology Group Not yet recruiting

8. The Effect of Ketone Ester Supplementation and Ketogenic Diet on Brain Plasticity in Overweight/Obese Adults

   Conditions: Overweight and Obesity; Cognitive Change; Psychophysiologic Reaction Interventions: Dietary Supplement: Ketone Monoester Supplementation; Dietary Supplement: Ketogenic diet Sponsors: University of Macau Not yet recruiting

9. Dopamine, Reward Learning and Sex Hormones

   Conditions: Hormonal Changes; Menstrual Cycle Interventions: Drug: Levodopa administration; Drug: Placebo administration Sponsors: University Hospital Tuebingen; German Research Foundation; Uppsala University Not yet recruiting

10. The Role of 68GA DOTATATE PET/CT In Breast Cancer Imaging

    Conditions: Breast Cancer Interventions: Diagnostic Test: 18F FDG PET/CT; Diagnostic Test: 68Ga DOTATATE PET/CT Sponsors: Celal Bayar University Completed

11. Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs

    Conditions: Neuroendocrine Tumors; GEP-NET Sponsors: IRCCS San Raffaele Active, not recruiting

12. EchoTip AcuCore Post-Market Clinical Study

    Conditions: Adenocarcinoma; Neuroendocrine Tumors; Hepatocellular Carcinoma; Cholangiocarcinoma; Malignant Lymphoma; Metastasis; Chronic Pancreatitis; Autoimmune Pancreatitis Interventions: Device: EchoTip AcuCore Sponsors: Cook Research Incorporated Not yet recruiting

13. Cessation of Somatostatin Analogues After PRRT in Mid-Gut Neuroendocrine Tumours

    Conditions: Neuroendocrine Tumors Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group Not yet recruiting

14. SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs

    Conditions: Gastro-entero-pancreatic Neuroendocrine Tumor Sponsors: Peking Union Medical College Hospital Not yet recruiting

15. Iconographic Registry of Pancreatobiliary Endoscopy Procedures

    Conditions: Pancreas Neoplasm; Cancer of Pancreas; Pancreatitis; Neuroendocrine Tumors Sponsors: IRCCS San Raffaele Recruiting

16. Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients

    Conditions: Neuroendocrine Neoplasm Sponsors: European Institute of Oncology Recruiting

17. YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.

    Conditions: Neuroendocrine Neoplasm; Adenocarcinoma Sponsors: European Institute of Oncology Recruiting

18. Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

    Conditions: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab; Drug: Chemotherapy Sponsors: UNICANCER; National Cancer Institute, France; GlaxoSmithKline Not yet recruiting

19. Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.

    Conditions: Adrenal Tumor Interventions: Procedure: laparoscopic right adrenalectomy Sponsors: Zagazig University Completed

20. Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

    Conditions: Gastroenteropancreatic Neuroendocrine Tumor; Radiotherapy Interventions: Other: Simultaneous 68Ga-DOTATOC PET-MRI Sponsors: Assistance Publique - Hôpitaux de Paris Recruiting

21. Clinical Application of the J-PET Scanner Prototype

    Conditions: Prostate Cancer; Prostatic Hyperplasia; Prostatic Neoplasms; Prostate Cancer Metastatic; Neuroendocrine Tumors; Neuroendocrine Carcinoma Interventions: Diagnostic Test: J-PET scan Sponsors: Jagiellonian University; University Hospital in Krakow Recruiting

22. Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

    Conditions: Small Cell Carcinoma of the Bladder; High Grade Neuroendocrine Tumors of the Urinary Tract Interventions: Drug: Lurbinectedin; Drug: Avelumab Sponsors: National Cancer Institute (NCI) Recruiting

23. Self-Care Training for Family Caregivers of Persons With Neurodegeneration

    Conditions: Caregiver Burden; Caregiver Stress Interventions: Other: Mindfulness Meditation; Other: Psychoeducation; Other: Wait list control Sponsors: Toronto Metropolitan University Recruiting

24. Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

    Conditions: Metastatic Chondrosarcoma; Locally Advanced Chondrosarcoma; Metastatic Sinonasal Adenocarcinoma; Locally Advanced Sinonasal Adenocarcinoma; Metastatic Large-cell Neuroendocrine Carcinoma; Locally Advanced Large-cell Neuroendocrine Carcinoma; Metastatic Olfactory Neuroblastoma; Locally Advanced Olfactory Neuroblastoma; Metastatic Sinonasal Undifferentiated Carcinoma; Locally Advanced Sinonasal Undifferentiated Carcinoma Interventions: Drug: Enasidenib Sponsors: National Cancer Institute (NCI) Recruiting

25. Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

    Conditions: Small Cell Carcinoma of the Bladder; Small Cell Carcinoma of the Urinary Tract; Squamous Cell Carcinoma of the Bladder; Squamous Cell Carcinoma of the Urinary Tract; Primary Adenocarcinoma of the Bladder; Primary Adenocarcinoma of the Urinary Tract; Renal Medullary Carcinoma; Squamous Cell Carcinoma of the Penis Interventions: Drug: Sacituzumab govitecan; Drug: Atezolizumab Sponsors: National Cancer Institute (NCI) Not yet recruiting

26. A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas Interventions: Drug: [212Pb] VMT-α-NET; Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT Sponsors: David Bushnell; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); Perspective Therapeutics Active, not recruiting

27. DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

    Conditions: Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin Sponsors: Boehringer Ingelheim Recruiting

28. Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Device: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT); Device: Photon Emission Tomography / CT (PET/CT); Drug: 64Cu-Dotatate; Drug: 177Lu-Dotatate Sponsors: University of Wisconsin, Madison Not yet recruiting

29. Intraoperative Hemodynamic Instability in Adrenalectomy for Pheochromocytoma.

    Conditions: adrenalDisease Interventions: Procedure: laparoscopic adrenalectomy Sponsors: Zagazig University Completed

30. Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

    Conditions: Neuroendocrine Carcinomas; Neuroendocrine Tumors; Carcinoma, Neuroendocrine; Carcinoma, Adrenocortical; Carcinoma, Adrenal Cortical Interventions: Drug: ADCT-701 Sponsors: National Cancer Institute (NCI) Recruiting

31. Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

    Conditions: Digestive System Neuroendocrine Tumor G1; Digestive System Neuroendocrine Tumor G2; Metastatic Digestive System Neuroendocrine Neoplasm; Metastatic Malignant Neoplasm in the Liver; Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2 Interventions: Procedure: Tumor Debulking; Drug: Lutetium Lu 177 Dotatate; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Drug: Copper Cu 64 Dotatate; Procedure: Positron Emission Tomography Sponsors: Vanderbilt-Ingram Cancer Center Recruiting

32. Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

    Conditions: Neuroendocrine Tumors; NET; Pancreatic Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Tumor; Pulmonary Neuroendocrine Tumor Interventions: Drug: nab-sirolimus Sponsors: Aadi Bioscience, Inc. Recruiting

33. Multicenter Trial of ESK981 in Patients With Select Solid Tumors

    Conditions: Pancreatic Adenocarcinoma; Adenosquamous Carcinoma; Pancreatic Neuroendocrine Tumor; Pancreatic Neuroendocrine Carcinoma; Gastrointestinal Neuroendocrine Tumor; Gastrointestinal Neuroendocrine Carcinoma; Neuroendocrine Prostate Carcinoma Interventions: Drug: ESK981 Sponsors: University of Michigan Rogel Cancer Center Recruiting

34. A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

    Conditions: Advanced Solid Tumors Interventions: Drug: INCB099280; Drug: axitinib Sponsors: Incyte Corporation Recruiting

35. Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

    Conditions: Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma; Unresectable Merkel Cell Carcinoma Interventions: Drug: Avelumab; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Tuvusertib Sponsors: National Cancer Institute (NCI) Recruiting

36. The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

    Conditions: Lung Cancer Interventions: Drug: Pioglitazone 45 mg; Drug: Placebo Sponsors: Pennington Biomedical Research Center Recruiting

37. A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

    Conditions: Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms Interventions: Drug: BI 764532; Drug: Ezabenlimab Sponsors: Boehringer Ingelheim Recruiting

38. LUTATHERA Injection General Use Result Survey

    Conditions: Somatostatin Receptor-positive Neuroendocrine Tumor Interventions: Other: LUTATHERA Sponsors: Novartis Pharmaceuticals Active, not recruiting

39. Vestibular Schwannoma Organoids

    Conditions: Vestibular Schwannoma Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center Recruiting

40. Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

    Conditions: Metastatic Midgut Neuroendocrine Tumor; Metastatic Midgut Neuroendocrine Tumor G1; Metastatic Midgut Neuroendocrine Tumor G2; Unresectable Midgut Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Everolimus; Drug: Lutetium Lu 177 Dotatate; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: National Cancer Institute (NCI) Recruiting

41. Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

    Conditions: Neuroendocrine Tumor Interventions: Drug: Al18F-octreotide Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting

42. Genetics of Appendix Cancer Study

    Conditions: Appendix Cancer; Appendiceal Cancer; Appendiceal Neoplasms; Appendiceal Mucinous Neoplasm; Appendiceal Adenocarcinoma; Appendiceal Carcinoid Tumor; Appendiceal Neoplasm Malignant Secondary; Appendix Adenocarcinoma; Appendix Mucinous Neoplasm; Appendix Tumor; Appendix Cancer Metastatic; Appendix NET; Low-Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Neoplasm; High Grade Appendix Mucinous Adenocarcinoma Interventions: Genetic: Genetic profiling; Other: Retrospective tissue procurement Sponsors: Andreana Holowatyj, PhD, MSCI Recruiting

43. Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

    Conditions: Metastatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Drug: Triapine Sponsors: National Cancer Institute (NCI) Recruiting

44. A Study of EBC-129 in Advanced Solid Tumours

    Conditions: Advanced Solid Tumours Interventions: Drug: EBC-129; Drug: Pembrolizumab Sponsors: EDDC (Experimental Drug Development Centre), A*STAR Research Entities; Parexel Recruiting

45. The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

    Conditions: Pheochromocytoma; Paraganglioma; Adrenalectomy; Status; Adrenergics Causing Adverse Effects in Therapeutic Use Interventions: Drug: Phenoxybenzamine Sponsors: Seoul National University Hospital Recruiting

46. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    Conditions: Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation; Metastatic Prostate Neuroendocrine Carcinoma; Metastatic Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Radiation: Gallium Ga 68-DOTATATE; Drug: Lutetium Lu 177 Dotatate; Procedure: Positron Emission Tomography Sponsors: National Cancer Institute (NCI) Recruiting

47. Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

    Conditions: Metastatic Pancreatic Neuroendocrine Tumor; Pancreatic Neoplasm; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Stage IV Pancreatic Neuroendocrine Tumor AJCC v8; Unresectable Pancreatic Neuroendocrine Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Lutetium Lu 177 Dotatate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography; Drug: Sunitinib Malate Sponsors: National Cancer Institute (NCI) Recruiting

48. Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

    Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor of Pancreas; Neuroendocrine Carcinoma Metastatic; Neuroendocrine Tumor Carcinoid; Carcinoid Tumor of GI System; Carcinoid Tumor; Paraganglioma; Pheochromocytoma Interventions: Drug: [212Pb]VMT-α-NET; Drug: [212Pb]VMT-α-NET Sponsors: Perspective Therapeutics Recruiting

49. A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

    Conditions: Small Cell Lung Cancer; Neuroendocrine Carcinoma Interventions: Drug: RO7616789; Drug: Tocilizumab Sponsors: Hoffmann-La Roche Recruiting

50. A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

    Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); Squamous Cell Carcinoma of Head and Neck; Colorectal Cancer; Gastric Cancer; Ewing Sarcoma; NTSR1 Expressing Solid Tumours; Neuroendocrine Differentiated (NED) Prostate Cancer Interventions: Drug: [225]-FPI-2059; Drug: [111In]-FPI-2058 Sponsors: Fusion Pharmaceuticals Inc. Recruiting